Cumberland Drug Patent Portfolio
Cumberland owns 6 orange book drugs protected by 30 US patents with Sancuso having the least patent protection, holding only 1 patent. And Vibativ with maximum patent protection, holding 11 patents. Given below is the list of Cumberland's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8952065 | Acetylcysteine composition and uses thereof | 10 Feb, 2035 | Active |
| US8722738 | Acetycysteine compositions and methods of use thereof | 06 Apr, 2032 | Active |
| US11806400 | Injectable ibuprofen formulation | 16 Mar, 2032 | Active |
| US9072661 | Injectable ibuprofen formulation | 16 Mar, 2032 | Active |
| US9072710 | Injectable ibuprofen formulation | 16 Mar, 2032 | Active |
| US9327028 | Acetylcysteine compositions and methods of use thereof | 21 Jul, 2031 | Active |
| US9012508 | Administration of intravenous ibuprofen | 14 Sep, 2030 | Active |
| US8735452 | Treating patients with intravenous ibuprofen | 30 Sep, 2029 | Active |
| US8871810 | Treating critically ill patients with intravenous ibuprofen | 30 Sep, 2029 | Active |
| US9114068 | Treating patients with intravenous ibuprofen | 30 Sep, 2029 | Active |
| US9138404 | Treating critically ill patients with intravenous ibuprofen | 30 Sep, 2029 | Active |
| US9295639 | Treating critically ill patients with intravenous ibuprofen | 30 Sep, 2029 | Active |
| US9649284 | Treating critically ill patients with intravenous ibuprofen | 30 Sep, 2029 | Active |
| US7531623 | Hydrochloride salts of a glycopeptide phosphonate derivative | 01 Jan, 2027 | Active |
| US8148356 | Acetylcysteine composition and uses therefor | 21 May, 2026 | Active |
| US8399445 | Acetylcysteine composition and uses thereof | 24 Aug, 2025 | Expired |
| US8653061 | Acetylcysteine composition and uses thereof | 24 Aug, 2025 | Expired |
| US7608282 | Transdermal granisetron | 22 Jan, 2025 | Expired |
| US6635618 | Glycopeptide phosphonate derivatives | 11 Sep, 2023 | Expired |
| US6858584 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin | 24 Aug, 2022 | Expired |
| US6727286 | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | 27 Nov, 2021 | Expired |
| US6872701 | Glycopeptide phosphonate derivatives | 05 Jun, 2021 | Expired |
| US7008923 | Glycopeptide phosphonate derivatives | 06 May, 2021 | Expired |
| US7208471 | Glycopeptide phosphonate derivatives | 01 May, 2021 | Expired |
| US7351691 | Glycopeptide phosphonate derivatives | 01 May, 2021 | Expired |
| US7544364 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin | 01 May, 2021 | Expired |
| US7700550 | Glycopeptide phosphonate derivatives | 01 May, 2021 | Expired |
| US8101575 | Glycopeptide phosphonate derivatives | 01 May, 2021 | Expired |
| US8158580 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin | 01 May, 2021 | Expired |
| US5723606 | Condensed benzazepine derivative and pharmaceutical composition thereof | 15 Dec, 2019 | Expired |
Latest Legal Activities on Cumberland's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cumberland.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 20 May, 2024 | US8158580 |
|
Expire Patent
Critical
| 26 Feb, 2024 | US8101575 |
|
Maintenance Fee Reminder Mailed
Critical
| 04 Dec, 2023 | US8158580 |
| Mail Patent eGrant Notification | 07 Nov, 2023 | US11806400 |
| Recordation of Patent eGrant | 07 Nov, 2023 | US11806400 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 07 Nov, 2023 | US11806400 |
| Patent eGrant Notification | 07 Nov, 2023 | US11806400 |
|
Recordation of Patent Grant Mailed
Critical
| 07 Nov, 2023 | US11806400 |
|
Email Notification
Critical
| 07 Nov, 2023 | US11806400 |
|
Email Notification
Critical
| 19 Oct, 2023 | US11806400 |
|
Issue Notification Mailed
Critical
| 18 Oct, 2023 | US11806400 |
|
Application Is Considered Ready for Issue
Critical
| 06 Oct, 2023 | US11806400 |
| Dispatch to FDC | 06 Oct, 2023 | US11806400 |
|
Issue Fee Payment Received
Critical
| 03 Oct, 2023 | US11806400 |
|
Issue Fee Payment Verified
Critical
| 03 Oct, 2023 | US11806400 |
Cumberland's Drug Patent Litigations
Cumberland's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 04, 2012, against patent number US9295639. The petitioner , challenged the validity of this patent, with Leo PAVLIV et al as the respondent. Click below to track the latest information on how companies are challenging Cumberland's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9295639 | December, 2012 |
Decision
(17 Sep, 2015)
| Leo PAVLIV et al | |
Cumberland Drug Patents' Oppositions Filed in EPO
Cumberland drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 30, 2008, by Boeters & Lieck. This opposition was filed on patent number EP04708393A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP04708393A | Apr, 2008 | Harrison Goddard Foote | Opposition rejected |
| EP04708393A | Apr, 2008 | BOETERS & LIECK | Opposition rejected |
Cumberland's Family Patents
Cumberland Drug List
Given below is the complete list of Cumberland's drugs and the patents protecting them.
1. Acetadote
Acetadote is protected by 6 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8952065 | Acetylcysteine composition and uses thereof |
10 Feb, 2035
(9 years from now)
| Active |
| US8722738 | Acetycysteine compositions and methods of use thereof |
06 Apr, 2032
(6 years from now)
| Active |
| US9327028 | Acetylcysteine compositions and methods of use thereof |
21 Jul, 2031
(5 years from now)
| Active |
| US8148356 | Acetylcysteine composition and uses therefor |
21 May, 2026
(4 months from now)
| Active |
| US8399445 | Acetylcysteine composition and uses thereof |
24 Aug, 2025
(4 months ago)
| Expired |
| US8653061 | Acetylcysteine composition and uses thereof |
24 Aug, 2025
(4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acetadote's drug page
2. Caldolor
Caldolor is protected by 11 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11806400 | Injectable ibuprofen formulation |
16 Mar, 2032
(6 years from now)
| Active |
| US9072661 | Injectable ibuprofen formulation |
16 Mar, 2032
(6 years from now)
| Active |
| US9072710 | Injectable ibuprofen formulation |
16 Mar, 2032
(6 years from now)
| Active |
| US9012508 | Administration of intravenous ibuprofen |
14 Sep, 2030
(4 years from now)
| Active |
| US8735452 | Treating patients with intravenous ibuprofen |
30 Sep, 2029
(3 years from now)
| Active |
| US8871810 | Treating critically ill patients with intravenous ibuprofen |
30 Sep, 2029
(3 years from now)
| Active |
| US9114068 | Treating patients with intravenous ibuprofen |
30 Sep, 2029
(3 years from now)
| Active |
| US9138404 | Treating critically ill patients with intravenous ibuprofen |
30 Sep, 2029
(3 years from now)
| Active |
| US9295639 | Treating critically ill patients with intravenous ibuprofen |
30 Sep, 2029
(3 years from now)
| Active |
| US9649284 | Treating critically ill patients with intravenous ibuprofen |
30 Sep, 2029
(3 years from now)
| Active |
| US6727286 | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
27 Nov, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caldolor's drug page
3. Sancuso
Sancuso is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7608282 | Transdermal granisetron |
22 Jan, 2025
(11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sancuso's drug page
4. Vaprisol
Vaprisol is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5723606 | Condensed benzazepine derivative and pharmaceutical composition thereof |
15 Dec, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vaprisol's drug page
5. Vaprisol In 5% Dextrose In Plastic Container
Vaprisol In 5% Dextrose In Plastic Container is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5723606 | Condensed benzazepine derivative and pharmaceutical composition thereof |
15 Dec, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vaprisol In 5% Dextrose In Plastic Container's drug page
Explore Our Curated Drug Screens
6. Vibativ
Vibativ is protected by 11 patents, out of which 10 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7531623 | Hydrochloride salts of a glycopeptide phosphonate derivative |
01 Jan, 2027
(11 months from now)
| Active |
| US6635618 | Glycopeptide phosphonate derivatives |
11 Sep, 2023
(2 years ago)
| Expired |
| US6858584 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
24 Aug, 2022
(3 years ago)
| Expired |
| US6872701 | Glycopeptide phosphonate derivatives |
05 Jun, 2021
(4 years ago)
| Expired |
| US7008923 | Glycopeptide phosphonate derivatives |
06 May, 2021
(4 years ago)
| Expired |
| US7208471 | Glycopeptide phosphonate derivatives |
01 May, 2021
(4 years ago)
| Expired |
| US7351691 | Glycopeptide phosphonate derivatives |
01 May, 2021
(4 years ago)
| Expired |
| US7544364 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
01 May, 2021
(4 years ago)
| Expired |
| US7700550 | Glycopeptide phosphonate derivatives |
01 May, 2021
(4 years ago)
| Expired |
| US8101575 | Glycopeptide phosphonate derivatives |
01 May, 2021
(4 years ago)
| Expired |
| US8158580 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
01 May, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vibativ's drug page